Compare RRBI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRBI | MNPR |
|---|---|---|
| Founded | 1998 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 613.0M | 587.4M |
| IPO Year | 2019 | 2019 |
| Metric | RRBI | MNPR |
|---|---|---|
| Price | $96.65 | $106.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | N/A | ★ $107.00 |
| AVG Volume (30 Days) | 88.4K | ★ 169.1K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | 28.89 | ★ 54.99 |
| EPS | ★ 1.81 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.72 | N/A |
| Revenue Next Year | $4.35 | N/A |
| P/E Ratio | $53.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $58.12 | $29.18 |
| 52 Week High | $98.85 | $112.57 |
| Indicator | RRBI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.40 | 78.25 |
| Support Level | $86.37 | $52.92 |
| Resistance Level | $98.28 | N/A |
| Average True Range (ATR) | 2.25 | 7.98 |
| MACD | 0.42 | 1.14 |
| Stochastic Oscillator | 74.90 | 79.76 |
Red River Bancshares Inc is the bank holding company for the red river bank. The principal business of the Bank is lending and accepting deposits from businesses, professionals, individuals, and public entities. The bank's primary deposit products are demand deposits, savings deposits, and time deposits. The bank maintains a diversified loan portfolio with a focus on commercial real estate (Owner Occupied and Non-Owner Occupied), one-to-four-family residential, commercial, and industrial loans, construction and development Loans, and others. also, provides Treasury Management Services, Private Banking Services, Brokerage Services, and Other Banking Services.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.